Chemours (NYSE:CC – Get Free Report) released its quarterly earnings data on Tuesday. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07), Zacks reports. Chemours had a positive return on equity of 42.63% and a negative net margin of 5.00%.The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the prior year, the company earned ($2.54) earnings per share. The business’s revenue was down 1.5% compared to the same quarter last year.
Chemours Trading Up 4.3%
CC stock traded up $0.63 during midday trading on Thursday, reaching $15.22. The stock had a trading volume of 2,993,411 shares, compared to its average volume of 3,073,437. The company has a quick ratio of 0.87, a current ratio of 1.82 and a debt-to-equity ratio of 18.98. Chemours has a twelve month low of $10.44 and a twelve month high of $28.67. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -7.97 and a beta of 1.43. The business has a fifty day simple moving average of $19.51 and a two-hundred day simple moving average of $20.06.
Chemours Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 14th. Chemours’s dividend payout ratio (DPR) is presently -18.32%.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on Chemours
Chemours News Summary
Here are the key news stories impacting Chemours this week:
- Positive Sentiment: Truist maintains a Buy rating: Truist Financial lowered its price target from $30 to $24 but retained a “buy” recommendation. The new target still implies approximately 57% upside from recent levels, providing a positive catalyst for the stock. Benzinga
- Positive Sentiment: Cash generation and year-over-year loss improvement: Chemours reported $114 million of free cash flow and $158 million of operating cash flow in the second quarter. Its $274 million net loss improved from a $380 million loss in the prior-year period, while Titanium Technologies sales increased 1% year over year. Chemours reports second-quarter results
- Neutral Sentiment: Dividend maintained: The company declared a quarterly dividend of $0.0875 per share, payable September 15 to shareholders of record August 14. The payment supports income-focused investors, though it does not materially change Chemours’ operating outlook. Chemours announces third-quarter dividend
- Neutral Sentiment: Full-year outlook was retained: Chemours continues to forecast 2026 sales growth of 1% to 5% and adjusted EBITDA of $775 million to $825 million. Full-year revenue guidance of $5.9 billion to $6.1 billion is broadly consistent with analyst expectations, while third-quarter revenue guidance of $1.5 billion to $1.6 billion is slightly below consensus.
- Negative Sentiment: Second-quarter results missed expectations: Adjusted earnings of $0.42 per share fell short of the roughly $0.43-$0.49 consensus range, and revenue of $1.591 billion was below the $1.65 billion estimate. Sales declined about 1% year over year, adjusted EBITDA fell to $247 million from $260 million, and Advanced Performance Materials revenue dropped 6%. Chemours reports second-quarter results
- Negative Sentiment: Litigation costs overshadow growth opportunities: Investors were disappointed that anticipated data-center and AI-related demand did not offset litigation-related costs and the underwhelming quarterly performance, pressuring sentiment after the earnings release. Chemours litigation costs and data-center growth
Hedge Funds Weigh In On Chemours
Several large investors have recently bought and sold shares of the business. Atlas Capital Advisors Inc. bought a new stake in shares of Chemours during the 4th quarter valued at $26,000. Aster Capital Management DIFC Ltd bought a new position in shares of Chemours in the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Chemours in the 3rd quarter worth $43,000. Advisory Services Network LLC acquired a new stake in shares of Chemours during the third quarter worth $54,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Chemours during the fourth quarter worth $61,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.
Chemours Company Profile
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
Featured Stories
- Five stocks we like better than Chemours
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
- Astera Labs’ Post-Earnings Pullback May Be Last Chance to Buy Below $360
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
